the feasibility of consecutive day dosing of high-dose cytarabine consolidation in aml
Published 5 months ago • 96 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
5:31
the role of venetoclax in older patients with aml
-
1:21
trends in allosct for good-risk aml: a longitudinal study
-
1:28
venetoclax & dose-reduced chemotherapy for the treatment of older adults with b-all and t-all
-
1:04
clad-ldac-ven induction therapy in aml: insights from a phase ii trial
-
2:14
update on the aml treatment landscape
-
1:21
intensive therapy of older aml
-
1:48
do all patients require maintenance therapy following allosct?
-
2:45
continuity of care for patients with hematological predispositions to aml
-
3:52
venetoclax & aml
-
2:17
the need to improve the quality of life of patients with aml undergoing allosct
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
2:01
aml: multiple problems requiring combined therapy
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml
-
1:33
sorafenib as maintenance therapy for patients with transplant-ineligible or post-allosct aml
-
2:13
haploidentical sct for the treatment of secondary aml
-
5:08
combining hypomethylating agents in aml
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
1:40
second-generation flt3 inhibitors in the treatment of flt3-itd aml
-
4:37
updates from uk ncri aml18